Key Slides: Complex Case Studies on Current HBV Management Strategies

Brief Clinical Care Options (CCO) presentation on using the EASL guidelines to determine treatment candidacy in patients with hepatitis B virus HBV.

Maria Buti, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: September 7, 2021 Expired: September 6, 2022

Clinical Care Options (CCO) expert commentary from Maria Buti, MD, on her approach to assessing patients with HBV for treatment candidacy in the setting of other host factors.

Maria Buti, MD Released: August 26, 2021

Clinical Care Options (CCO) expert commentary from George Lau, MD, on the importance of screening patients for hepatitis B prior to immunosuppressive therapy initiation

George Lau, MBBS (HKU), MD (HKU), FRCP (Edin, Lond), FAASLD (USA) Released: August 23, 2021

Dr. Takeshi Saito on increasing detection of HBV/HDV coinfection, especially among HBsAg-positive persons, examples from Mongolian population in California from Clinical Care Options (CCO)

Takeshi Saito, MD, PhD Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: August 20, 2021 Expired: August 19, 2022